Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

View Full Paper
Ask AI
Bookmark
Share

Authors

YCYaël C. CohenRBRoss BakerMLMark‐David Levin

Discussion

Loading...

Member takes

Overview

A phase 3 trial shows daratumumab improves progression-free survival in high-risk smoldering multiple myeloma patients, suggesting early treatment benefits over monitoring.

Key Points

  • Daratumumab treatment improved progression-free survival significantly compared to active monitoring in high-risk patients.
  • Patients on daratumumab had favorable outcomes with a hazard ratio of 0.36 for progression or death versus monitoring.
  • Analysis included patient demographics, risk stratification, and safety outcomes, showing no major safety concerns with daratumumab.
  • Promising findings support early intervention with daratumumab, enhancing treatment approaches for smoldering multiple myeloma.

Cite This Study

Cohen et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e092https://doi.org/10.1182/blood-2025-372
View Full Paper
Ask AI
Bookmark
Share